These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 8401354

  • 1. Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1).
    Loewenthal E, Weiss L, Samuel S, Or R, Slavin S.
    Bone Marrow Transplant; 1993 Aug; 12(2):109-13. PubMed ID: 8401354
    [Abstract] [Full Text] [Related]

  • 2. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

  • 3. Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation.
    Weiss L, Reich S, Slavin S.
    Bone Marrow Transplant; 1990 Oct; 6(4):229-33. PubMed ID: 2085696
    [Abstract] [Full Text] [Related]

  • 4. The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation.
    Abdul-Hai A, Weiss L, Ergas D, Resnick IB, Slavin S, Shapira MY.
    Bone Marrow Transplant; 2007 Nov; 40(9):891-6. PubMed ID: 17768389
    [Abstract] [Full Text] [Related]

  • 5. Differential killing of murine B-cell leukemia (BCL1) by photosensitization with merocyanine 540: implications for autologous bone marrow transplantation.
    Mumcuoglu M, Weiss L, Spivak J, Slavin S.
    Bone Marrow Transplant; 1989 Mar; 4(2):143-6. PubMed ID: 2650782
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE, Horan JT, Liesveld JL, Abboud CN, Zwetsch LM, Senf ES, Constine LS, Raubertas RF, Passarell JA, DiPersio JF.
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB, Elkin G, Khitrin S, Slavin S.
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [Abstract] [Full Text] [Related]

  • 10. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
    Marks DI, Forman SJ, Blume KG, Pérez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM.
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):438-53. PubMed ID: 16545728
    [Abstract] [Full Text] [Related]

  • 11. A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation.
    Panigrahi S, Morecki S, Yacovlev E, Gelfand Y, Kassir J, Slavin S.
    Exp Hematol; 2004 Aug; 32(8):756-64. PubMed ID: 15308327
    [Abstract] [Full Text] [Related]

  • 12. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
    Weiss L, Reich S, Slavin S.
    Bone Marrow Transplant; 1995 Sep; 16(3):457-61. PubMed ID: 8535320
    [Abstract] [Full Text] [Related]

  • 13. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [Abstract] [Full Text] [Related]

  • 14. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
    Yoshimi A, Nannya Y, Sakata-Yanagimoto M, Oshima K, Takahashi T, Kanda Y, Motokura T, Chiba S, Kurokawa M.
    Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
    Nilsson C, Forsman J, Hassan Z, Abedi-Valugerdi M, O'Connor C, Concha H, Jansson M, Hassan M.
    Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S, Ringdén O, Aschan J, Hägglund H, Ljungman P, Mattsson J, Remberger M.
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.